- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration
- Meeting Date: May 2024
- Public Summary Document (PSD) May 2024 PBAC Meeting - (PDF 636KB)
- Public Summary Document (PSD) May 2024 PBAC Meeting - (Word 245KB)
Aflibercept – May 2024
Aflibercept (CNV): Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL); Eylea®
Last updated
30 May 2025